芪精回心汤治疗冠脉微血管心绞痛:随机对照多中心试验方案
这是一项前瞻性随机对照试验方案,计划纳入150例冠脉微血管心绞痛患者,在规范西药治疗基础上加用芪精回心汤治疗12周并随访至24周。主要评价心绞痛临床疗效与中医证候疗效,次要指标包括西雅图心绞痛量表评分、血脂、心电图和超声心动图诊断,附加指标为内皮功能与免疫炎症因子,全程监测不良事件。
要点
- 芪精回心汤作为西药辅助治疗冠脉微血管心绞痛,疗程12周,随访至24周。
- 主要疗效指标为心绞痛临床疗效和中医证候疗效。
- 试验计划纳入150例患者,随机分为两组,全程监测不良事件。
核心结论
- 本试验旨在评价在规范西药治疗基础上加用芪精回心汤治疗冠脉微血管心绞痛的临床有效性与安全性。
- 试验结果将为芪精回心汤用于冠脉微血管心绞痛提供高级别临床研究证据。
研究设计与样本
- 这是一项前瞻性随机对照试验,计划纳入150例冠脉微血管心绞痛患者。
- 患者在Western药物(西药)治疗基础上随机分为两组,试验组接受芪精回心汤治疗12周,并于24周随访。
关键数值与推荐
- 主要指标为心绞痛临床疗效和中医证候疗效。
- 次要指标包括西雅图心绞痛量表评分、血清脂质水平、心电图和超声心动图诊断。
- 附加指标为内皮功能和免疫炎症因子。
- 试验全程监测不良事件。
临床怎么用
- 在中国,中西医结合常用于心绞痛治疗,本方案在标准化西药基础上加用芪精回心汤。
- 该方案若获阳性结果,可为冠脉微血管心绞痛的中西医结合治疗提供循证依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the increased understanding of heart disease, microvascular angina (MVA) is receiving greater attention from clinicians. Studies have shown that patients with MVA have significantly higher major cardiovascular events and all-cause mortality than the control population, and the search for effective treatments is of great clinical importance. Both basic and clinical studies have shown that Qi-Jing Hui-Xin Decoction (QJHX) can relieve angina symptoms and improve clinical efficacy, but there is a lack of high-quality clinical studies to provide a research basis. This article introduces the evaluation protocol of QJHX for the adjunctive treatment of MVA. METHODS/DESIGN: This is a prospective randomized controlled trial. The trial will enroll 150 patients with MVA. On the basis of Western drug treatment, patients will be randomized into two groups, and the experimental group will receive QJHX treatment for 12 weeks and follow-up at 24 week. The primary indicators are the clinical efficacy of angina pectoris and the evidence of traditional Chinese medicine (TCM) efficacy. Secondary indicators are the Seattle Angina Scale score, serum lipid levels, electrocardiogram, and echocardiogram diagnosis. Additional indicators are endothelial function and immunoinflammatory factors. Adverse events will be monitored throughout the trial. DISCUSSION: Integrated traditional Chinese and Western medicine is commonly used for angina in China. This study will evaluate the clinical effectiveness and safety of adding QJHX based on standardized Western medications. The results of the trial will provide high-level clinical research-based evidence for the application of QJHX in MVA. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1900027015 . Registered on 28 October 2019.
引用
- Sun Y, Huang C, Huo L, et al. Efficacy and safety of Qi-Jing Hui-Xin Decoction in the treatment of coronary microvascular angina: study protocol for a randomized, controlled, multi-center clinical trial. Trials. 2021. PMID: 34419124. doi:10.1186/s13063-021-05508-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。